Clinical Trials
5 trialsNCT01093183 2023-09-13
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
University of Nebraska
Phase 1/2 Terminated
NCT00975806 2019-11-25
Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma
Celgene
Phase 1/2 Terminated
NCT01342172 2019-04-23
Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma
Icahn School of Medicine at Mount Sinai
Phase 1/2 Terminated
NCT00933426 2016-10-26
Lenalidomide and Paclitaxel in Prostate Cancer
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00179738 2005-11-23
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Celgene
Phase 2 Terminated